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Neurodegenerative diseases have been intensively studied, but a comprehensive understanding of their
pathogenesis remains elusive. An increasing body of evidence suggests that non-cell-autonomous
processes play critical roles during the initiation and spatiotemporal progression or propagation of the domi-
nant pathology. Here, we review findings highlighting the importance of pathological cell-cell communication
in neurodegenerative disease. We focus primarily on the accumulating evidence suggesting dysfunctional
crosstalk between neurons and astroglia, neurons and innate immune system cells, as well as cellular
processes leading to transmission of pathogenic proteins between cells. Insights into the complex intercel-
lular perturbations underlying neurodegeneration will enhance our efforts to develop effective therapeutic
approaches for preventing or reversing symptomatic progression in this devastating class of human
diseases.Introduction
Despite intensive study over the past three decades, neurode-
generative diseases remain insufficiently understood, precluding
rational design of therapeutic interventions that can reverse or
even arrest the progressive loss of neurological function. The
identification and study of genetic mutations responsible for
numerous neurodegenerative syndromes have led to several
compelling theories on disease pathogenesis. Some of these
theories, such as those involving a central role for protein mis-
folding, mitochondrial dysfunction, oxidative stress, excitotoxic-
ity, and transcriptional dysregulation, have been proposed for
a wide variety of neurodegenerative disorders. Data supporting
a role for each of these pathogenic processes in a variety of clin-
ical syndromes has been generated from primary patient mate-
rial (usually postmortem), in vitro cell culture, and primary neuron
models, invertebrate and vertebrate model systems, and most
recently, induced pluripotent stem cell modeling. These wide-
ranging disease studies, coupled with powerful model systems,
have yielded a wealth of information regarding pathways of
neuronal demise in the face of mutant gene expression and
have revealed neuroprotective mechanisms that effectively
counter pathogenic cellular processes.
However, even with this wealth of information, effective inter-
ventions for these diseases remain agonizingly elusive. Why?
One potential answer to this question is that experimentation
into the basis of neuronal degeneration and death has generated
hypotheses of pathogenesis that are overly focused on (1) late-
stage events and (2) events that are best modeled in isolated
neurons. For example, many groups have promoted the idea
that protein misfolding is a critical step in neurodegeneration.
This theory posits that once the capacity of a neuron to handle
misfolded proteins is exceeded, mitochondrial dysfunction
results, thereby promoting increased oxidative stress—which886 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.in turn promotes the further accumulation of damaged proteins
that must be handled by an already overwhelmed protein degra-
dation system (Saxena and Caroni, 2011; Williams and Paulson,
2008). Under this ‘‘proteinopathy’’ theory, interventions that
would enhance the capacity of neurons to handle misfolded
proteins, increase mitochondrial reserves, or reduce oxidative
stress should prevent neurodegeneration. Unfortunately, the
proposed ‘‘proteinopathy’’ cascade of events cannot explain
a number of important factors critical for understanding neuro-
degeneration. For example, mutant proteins are ubiquitously
expressed by neurons (and typically nonneuronal cells in
the CNS), yet for each disorder, neurodegeneration occurs in
selectively vulnerable cell populations. If a common molecular
cascade can explain pathogenesis, why then are certain types
of neurons more vulnerable than others? Furthermore, most
neurodegenerative disease, associated with protein misfolding,
develops in middle or late adulthood, but the responsible
proteins are expressed throughout the patient’s lifetime. How
does age or time influence the pathogenic potential of a mutant
ormisfolded protein that characterizes a specific disease? Some
speculate that the proteinopathy cascade may manifest in vivo
only during the final stages of the degenerative process. Thus,
the anatomic, functional, or age-dependent features that drive
the proteinopathy cascade in subsets of neurons at a specific
time remain undefined.
One hypothesis potentially explaining how neurodegenerative
diseases are initiated in their characteristic patterns was
adopted from the study of cancer. The ‘‘multi-hit’’ theory of
carcinogenesis addresses a number of key features of this
disease, including the increased incidence of cancer with age
and the clear influence of both genetic background and
environmental exposures. That neurodegenerative disorders
are similarly initiated by a combination of acquired and inherited
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the epidemiology of sporadic disease (Mahley et al., 2007;
Sulzer, 2007).We hypothesize that amulti-hit paradigm involving
the impact of synergistic forms of cellular dysfunction via cell-cell
interaction may account for both age dependence and regional
specificity of neurodegeneration for a specific disorder. A corol-
lary to this hypothesis is that disease-causing mutations result in
cell type specific dysfunctions, which individually do not cause
the full spectrum of disease symptoms, but in concert and
over time will result in the distinct patterns of neurological
dysfunction and/or neurodegeneration that characterize a given
disorder.
Support for this hypothesis is found in numerous studies
suggesting that disease pathogenesis in neurodegenerative
syndromes involves communication between different cell
types. Interacting cell types in different diseases are one unit
of organization, defined by certain populations of neurons,
surrounding glia, elements of the neurovascular interface, and
CNS innate immune system. This hypothesis is consistent with
recent, intriguing evidence for the prion-like spread of patho-
genic misfolded proteins from cell to cell (Aguzzi and Rajendran,
2009). Given the wide range of non-cell-autonomous mecha-
nisms potentially at play and the inherent challenge of describing
each in great depth, our goal with this review is to rather present
a broad overview of select types of cell-cell communication that
are disrupted, altered, or co-opted to promote disease patho-
genesis in neurodegenerative disease.
Non-Cell-Autonomous Degeneration
The majority of human neurodegenerative diseases initially
involve a discrete set of selectively vulnerable neurons. Identifi-
cation of the genetic mutations responsible for familial forms of
a variety of neurodegenerative disorders—such as amyotrophic
lateral sclerosis (ALS), Parkinson’s disease (PD), or Alzheimer’s
disease (AD)—has provided keen insights into molecular mech-
anisms of neuronal injury. However, identifying the toxic gain or
loss of function imparted by disease-causing mutations often
fails to explain disease phenotypes, because expression of the
mutant protein is seldom restricted to the affected neuronal
populations. Indeed, when the causal mutant gene product of
several inherited neurodegenerative diseases is selectively
expressed in the vulnerable neuron populations, some mouse
models do not yield the complete disease phenotype (Boille´e
et al., 2006; Brown et al., 2008; Gu et al., 2007; Yvert et al.,
2000). Conversely, widespread expression of disease genes in
multiple CNS cell types can recapitulate disease patterns akin
to the human disease being modeled, sometimes even when
the disease gene is not expressed in the selectively vulnerable
population (Garden et al., 2002). Thus selective neuronal vulner-
ability in neurodegenerative disease likely arises from the com-
plex interactions between interconnected cell types. When the
net effect of dysfunction in one CNS cell type is the degeneration
of a second neighboring or interconnected cell type, the process
is known as ‘‘non-cell-autonomous’’ neurodegeneration.
There is strong evidence for non-cell-autonomous neurode-
generation in a number of neurological diseases. For example,
human transplantation studies in Parkinson’s disease patients
have shown that cellular and molecular pathology will developin healthy neurons grafted into the brains of affected patients
(Dawson, 2008). This finding suggests that replacement of
selectively vulnerable neuronal populations may not be sufficient
to alleviate disease. Several experimental models of inherited
neurodegenerative disease provide direct evidence for non-
cell-autonomous degeneration. These include examples of
neurodegeneration induced in one cell type, when the disease
gene is restricted to a surrounding or connecting cell, or when
selective removal of a disease-causing gene from one cell
population prevents toxicity in a second cell population despite
continued expression of the mutant protein (Clement et al.,
2003; Gu et al., 2005). That selective expression of mutant
proteins in surrounding nonneuronal cells (e.g., glia) can induce
neurodegeneration has also provided strong experimental
evidence supporting the hypothesis of non-cell-autonomous
pathogenesis (Custer et al., 2006; Lioy et al., 2011). In the
following sections, we will discuss evidence supporting the
involvement of aberrant cell-cell communication between neu-
rons, neurons and glia, as well as prion-like spreading of aggre-
gate proteins between cells, in neurodegeneration.
Dysfunctional Communication between Neurons
How does dysfunction in one type of neuron lead to degenera-
tion in a distinct population of neurons? This question can be
parsed according to the different types of interactions known
to occur between neurons. In general, neural circuits involve
presynaptic input from one population of neurons to a separate
population of neurons that comprise the postsynaptic target
cells. During nervous system development, some neurons
require the formation of synaptic circuitry for sustained survival
(Linden, 1994). In a variety of sensory systems, not only are
appropriate physical connections a prerequisite for neuronal
survival, but the synapses must also be activated by sufficient
sensory input (Aamodt and Constantine-Paton, 1999; Harris
and Rubel, 2006). This exquisite sensitivity for appropriate
synaptic circuitry typically has a brief developmental time
course, known as the ‘‘critical period’’ during which loss of
normal synaptic input can lead to neurodegeneration (Harris
and Rubel, 2006). Neurons of the adult mammalian brain appear
more robust in the face of lost sensory experience, suggesting
that once neural circuits are well established, the individual
components of the circuit become less interdependent. How-
ever, studies performed using a range of approaches demon-
strate that certain adult neurons are susceptible to second order
neurodegeneration (Al-Abdulla and Martin, 1998; Al-Abdulla
et al., 1998; Baquet et al., 2004; Martin et al., 2003; Marty
and Peschanski, 1995; Rossi and Strata, 1995). For example,
Huntington’s disease (HD), an inherited neurodegenerative
disease caused by a CAG—polyglutamine repeat expansion in
the huntingtin gene—results in the atrophy and degeneration of
GABAergic medium spiny neurons (MSNs) in the caudate and
putamen. However, cortical neuron degeneration is also an
important feature of HD pathology (Sapp et al., 2001; Vonsattel
et al., 1985). Interestingly, when the Cre/lox system was
employed to express mutant huntingtin protein in a cell-type-
specific manner, cortical neurodegeneration could not be
achieved in a cell autonomous manner (Gu et al., 2005). This
study suggested that additional neuronal cell types mustNeuron 73, March 8, 2012 ª2012 Elsevier Inc. 887
Figure 1. A Variety of Non-Cell-Autonomous Factors Influence Neuronal Survival
Neurons receive synaptic input (1), delivering both neurotransmitters and neurotrophic factors (2) that sustain neuronal survival. Neurodegenerative diseases can
alter synaptic input by inhibiting anterograde axonal transport (3) and/or axon degeneration (4), resulting in decreased release of transmitters and neurotrophic
peptides. (5) Failed retrograde transport as well as molecular dysfunction in target neurons or in non-neural target organs (e.g., muscle and blood vessels) can
also damage presynaptic neurons, mimicking events that occur during development, when pathways of target-dependent neuronal survival are active.
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of cortical excitatory neurons. However, these experiments did
not specifically reveal which afferent inputs to, or synaptic
targets of, cortical neurons are involved in mediating their even-
tual degeneration.
The observation that inherited forms of neurodegeneration
may require expression of the disease-causing protein more
broadly than in the selectively vulnerable population of neurons,
suggests that patterns of regional or cell-type-specific neurode-
generation result from dysfunction in one small population of
the initially affected neurons, leading to waves of secondary
changes in other neuron populations (Figure 1). This second
order neuronal dysfunction can develop in a bidirectional
manner, resulting either from loss of afferent input or postsyn-
aptic targets, and/or defects in the molecular machinery at the
synapse that disrupt neurotransmission and plasticity, which888 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.frequently precede structural-anatomic alterations. In the follow-
ing section, we will focus primarily on the role of synaptic inputs
in the evolution of neurodegenerative pathology.
Dysfunctional Input
Presynaptic inputs influence the function and health of their
target neurons in a variety of ways. One of the most extensively
studied means by which afferent input can influence the health
and survival of a target cell population is through the delivery
of neurotrophic factors. Loss of prosurvival neurotrophic factors
has been hypothesized to contribute to the pathogenesis of
several neurodegenerative disorders. Examples include nerve
grown factor (NGF) in AD, glial-derived neurotrophic factor
(GDNF) in PD, and both insulin-like growth factor-1 (IGF-1) and
vascular endothelial growth factor (VEGF) in ALS (Mickiewicz
and Kordower, 2011; Rangasamy et al., 2010; Sakowski et al.,
2009; Wyatt and Keirstead, 2010; Zuccato and Cattaneo,
Neuron
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in HD, where several lines of evidence suggest that a key factor
contributing to the selective vulnerability of MSNs in HD is
reduced delivery of brain-derived neurotrophic factor (BDNF)
from cortical afferent input. Reduced cortical BDNF expression
is sufficient to induce age-related degeneration of MSNs (Baquet
et al., 2004), suggesting that this mechanism can account for
several aspects of selective vulnerability in these neurons. HD
patient samples and mouse models both demonstrate reduced
BDNF in the caudate and putamen (Canals et al., 2004; Ferrer
et al., 2000), resulting from the effect of mutant huntingtin on
BDNF gene transcription and/or the anterograde transport of
BDNF to the presynaptic terminal (Gauthier et al., 2004; Zuccato
et al., 2001).
Another mechanism by which communication from afferents
may negatively impact the survival or function of a selectively
vulnerable population is through a change in the actual pattern
of synaptic activity onto the target cells. In this scenario, degen-
eration in second order neurons can develop either from
decreased synaptic input, or when afferents become dysfunc-
tional—leading to overstimulation/excitotoxicity of the target
population. Decreased synaptic input has been described in
various animal models of neurodegeneration (Barnes et al.,
2011; Mentis et al., 2011). One such example was recently re-
ported using an animal model of spinal muscular atrophy
(SMA). Patients with SMA inherit a motor neuron degenerative
disorder caused by loss of function of the survival motor
neuron (SMN) protein. In a mouse model of SMA, loss of motor
function precedes loss of motor neurons (Le et al., 2005). To
explore what influences motor neuron function prior to neurode-
generation, Mentis et al. (2011) examined the primary afferent
input and found that loss of synaptic input from sensory spindle
afferents followed the temporal and topographic pattern of
later motor neuron loss. Treatment with a histone deacetylase
inhibitor, an intervention that improves motor function in this
mouse model, also improved synaptic input from muscle
spindle afferents (Mentis et al., 2011). Since a treatment that
prevents reduction of the muscle spindle afferents also amelio-
rated motor neuron loss, this paper suggests that that loss of
afferent input may contribute to eventual motor neuron degener-
ation in SMA.
A second example of decreased synaptic input contributing to
neurodegeneration involves the spinocerebellar ataxias (SCAs),
a group of neurodegenerative disorders that predominantly
affect neurons in the brainstem and cerebellum involved inmotor
coordination and balance. Spinocerebellar ataxia type 1 (SCA1)
is a CAG repeat disorder characterized by a selective degenera-
tion of cerebellar Purkinje cells (PCs). PCs receive excitatory
synaptic input from two cell types, cerebellar granule neurons
and inferior olive (IO) neurons, whose climbing fibers (CFs)
synapse on PC dendrites in the cerebellar molecular layer. It
has recently been reported that CF input is reduced well before
PC degeneration occurs in several mouse models of SCA1
(Barnes et al., 2011; Duvick et al., 2010). Furthermore, using
a conditional expression system, one study found that the effect
of the disease gene on CF input occurs during the first 5 post-
natal weeks (Barnes et al., 2011). When disease gene expression
was prevented during this early period, loss in CF input waspartially reversed and PC degeneration was completely pre-
vented (Barnes et al., 2011). Since expression of mutant
ataxin-1 in this model is selectively restricted to PCs, the interac-
tion between CF and PC neurons must be occurring in a bidirec-
tional fashion. Thus, PCs expressing mutant protein prevent
normal synaptic structure and function of CFs, through an
unknown signaling mechanism, and subsequent CF dysfunction
early in the course of disease contributes to the eventual PC
degeneration.
Additional evidence for the importance of CF input to PC
survival comes from the study of spinocerebellar ataxia type 7
(SCA7), another polyglutamine expansion disorder (Garden
and La Spada, 2008). Both cerebellar PCs and IO neurons are
among the selectively vulnerable populations in SCA7. When
SCA7 was modeled in mice via transgenic expression of human
mutant ataxin-7 protein, evidence for non-cell-autonomous
degeneration of cerebellar PCs was noted early on. One group
directed expression of the mutant gene specifically to PCs and
did not observe significant pathology (Yvert et al., 2000). We
employed an approach where mutant gene expression was
expressed ubiquitously in the CNS, with the exception of PCs,
and observed early onset ataxia and PC degeneration (Garden
et al., 2002). Taken together, these studies indicate that in
SCA7, PCs degenerate in response to signals from their
surrounding environment. IO neurons also undergo degenera-
tion in SCA7 models (Wang et al., 2010). Thus, reduced CF input
could be a driving factor in PC degeneration. Eliminating mutant
protein expression concurrently in both IO neurons and PCs
concomitantly ameliorated the behavioral phenotype in the
SCA7 mice (Furrer et al., 2011). Since prior studies had shown
that expression of the mutant protein was neither necessary
(Garden et al., 2002) nor sufficient (Yvert et al., 2000) to induce
PC degeneration in a SCA7 model, our results support the
hypothesis that degeneration of IO neurons and resulting loss
of CF input contribute to PC degeneration in SCA7.
Abnormal Neuron-Glia Interactions
Astrocytes Perform a Variety of Important Roles
Although the vast majority of the neuroscience research per-
formed in the 20th century took a neuron-centric view, a growing
appreciation of the importance of non-neural cells in nervous
system function sparked a paradigm shift in our understanding
of how the CNS is organized and operates, by the close of the
20th century. This revolution was driven by seminal studies that
increasingly recognized astrocytes as not only support cells for
neurons, but also as partners in fundamental neural processes
(Bezzi et al., 1998; Parpura et al., 1994; Pasti et al., 1997). It is
now well established that astrocytes can sense and respond to
neuronal activity, as they possess receptors for neurotransmit-
ters (Jourdain et al., 2007). The discovery of neurotransmitter
release from astrocytes led to further characterization of these
so-called ‘‘gliotransmitters,’’ and has revealed a potentially
robust mechanism of neuron—astrocyte crosstalk during gluta-
matergic neurotransmission (Rossi and Volterra, 2009). Careful
histological and ultrastructural studies have documented an
exquisitely refined organization of neuronal synaptic networks
and astrocyte support networks. Astrocytes make up as much
as 50% of the brain’s volume, and they are organized intoNeuron 73, March 8, 2012 ª2012 Elsevier Inc. 889
Figure 2. Astrocyte Dysfunction in Neurodegenerative Disease
Astrocytes perform a variety of functions reflecting their communication and close interactions with neurons. Here we see a representative astrocyte (blue)
engaging in various activities, which when disrupted or altered, can lead to dysfunction and degeneration of neurons (green):
(A) Astrocytes (blue) release neurotrophic factors (yellow smiley faces), and loss of neurotrophic factor release has been implicated in a number of neurological
disorders. Alternatively, astrocytes can release toxic factors (red frown faces), which are believed to be a feature of motor neuron disease and possibly other
disorders, as delineated in the section on Astrocyte-Derived Toxicity.
(B) Neurons (green) release neurotransmitters to propagate signals between each other, and these neurotransmitters must be removed from the synaptic cleft in
order to prevent persistent activation, a pathological process known as ‘‘excitotoxicity.’’ Astrocytes (blue) have transporters on their cell membranes to mediate
neurotransmitter uptake, and impairment in neurotransmitter uptake by astrocytes can contribute to neuron dysfunction and degeneration.
(C) Astrocytes (blue) shuttle metabolites (e.g., lactate) between blood vessels (red) and neurons (green), as shown here. Disturbances in this metabolic coupling
can result in neuron dysfunction.
(D) Astrocytes form the blood brain barrier in cooperation with cells lining blood vessels. The breakdown of the blood-brain barrier at the level of the astrocytemay
also occur in certain neurodegenerative diseases.
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many as 100,000 synapses can be located (Benarroch, 2005).
In such regions, astrocytes extend their cell membranes into
and among neuronal synapses, forming intermingled and closely
interdigitating areas of direct apposition, which facilitates
rapid and efficient removal of neurotransmitters from synaptic
clefts. Astrocytes also extend their cell membranes along
capillaries, and form ‘‘endfoot’’ processes, which create the
blood-brain barrier (Benarroch, 2005). The positioning of astro-
cytes in this way enables them to regulate vascular blood flow
and nutrient delivery based upon neuronal activity—processes
referred to respectively as ‘‘neurovascular coupling’’ and ‘‘meta-
bolic coupling.’’ By being adjacent to capillaries, astrocytes
are poised to respond to extracellular signals sent over long
distances and thus participate in the elaboration of inflammatory
responses initiated upon activation of microglia—the resident
immune cells of the CNS (Glass et al., 2010). Hence, astrocytes
appear to be central players in the pathological cell-cell commu-
nication that is now emerging as a defining feature of many
neurodegenerative disorders (Figure 2).890 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.Astroglial Loss of Function: Perturbations
in Glutamate Handling
Crucial to the process of synaptic neurotransmission is the timely
removal of glutamate from the synaptic cleft upon release and
activation of postsynaptic glutamatergic receptors. Failure to
eliminate glutamate from the synapse leads to continued activa-
tion of postsynaptic and extrasynaptic glutamate receptors. This
persistent activation drives excess Ca2+ into neurons, resulting
in ‘‘excitotoxicity’’ culminating in neuron cell death, once the
capacity of the neuron to safely sequester Ca2+ is exceeded.
To achieve rapid and efficient glutamate removal at the synapse,
higher organisms have evolved a family of five glutamate trans-
porters known as the excitatory amino acid transporters
(EAATs). Of the five EAATs, EAAT1 (formerly known as GLAST)
and EAAT2 (formerly known as GLT-1) are predominantly ex-
pressed on astroglia.
Glutamate excitotoxicity due to impaired function of EAAT1 or
EAAT2 has been proposed to contribute to neurodegeneration in
ALS, HD, and SCA7 (Ilieva et al., 2009). Best studied in ALS,
a rapidly progressive combined upper motor neuron—lower
Neuron
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as this glial glutamate transporter is estimated to remove 90%
of the neurotransmitter glutamate from the motor neuron
synapse (Rothstein et al., 1996). Initial studies on transgenic
mice generated to model a familial form of ALS (ALS1), due to
mutations in superoxide dismutase 1 (SOD1), yielded evidence
for reduced expression of EAAT2 (Bruijn et al., 1997), a process
that may involve apoptotic pathway activation culminating in the
production of activated caspase-3 (Boston-Howes et al., 2006).
Elevated glutamate levels in the cerebrospinal fluid of sporadic
ALS patients, however, independently suggest that excitotoxic-
ity is contributing to the disease process in sporadic cases
(Spreux-Varoquaux et al., 2002), consistent with studies docu-
menting EAAT2 reductions in sporadic ALS spinal cord material
(Rothstein et al., 1995). While the basis of the EAAT2 expression
reduction in sporadic ALS may involve altered EAAT2 splicing in
astrocytes (Lin et al., 1998), more recent work indicates that
a loss of upper motor neuron-lower motor neuron connectivity
might lead to reduced transcription of EAAT2 in astrocytes
(Yang et al., 2009). Recent high throughput drug screens have
further identified a compound, ceftriaxone, capable of inducing
EAAT2 expression and modestly extending the lifespan of
ALS1 SOD1 G93A transgenic mice (Rumbaugh et al., 2007).
Although the importance of dysfunctional astrocyte glutamate
handling for ALS disease progression is not entirely clear, clinical
trials are now underway to assess whether boosting astrocyte
function with ceftriaxone will be an effective therapy for this
currently untreatable disorder.
Interestingly, the SCA7 disease protein—ataxin-7—is widely
expressed throughout the nervous system in astroglia as well
as nerve cells (Custer et al., 2006). As previously discussed,
cell-type-specific expression studies of polyQ-expanded
ataxin-7 revealed that non-cell-autonomous mechanisms may
be involved in Purkinje cell degeneration characteristic of
SCA7 (Garden et al., 2002). As cerebellar Purkinje cell neurons
are intimately associated with specialized astroglial cells known
as the Bergmann glia, we considered the role of Bergmann glia
dysfunction in SCA7 disease pathogenesis (Custer et al.,
2006). We found that Bergmann glia-specific transgenic expres-
sion of ataxin-7-92Q in mice was sufficient to produce ataxia
and Purkinje cell degeneration, and that reduced EAAT1 expres-
sion precipitates the excitotoxic demise of cerebellar Purkinje
cell neurons. This study did not however implicate astrocytes
as the primary mediator of PC degeneration in SCA7 mice, since
glial-driven expression resulted in a milder phenotype than
animals with more widespread expression of polyQ-ataxin-7.
Using a BAC transgenic and cell-type-specific Cre-recombinase
driver lines, we further determined that expression of mutant
ataxin-7 protein is deleterious in multiple cell types to different
extents (Furrer et al., 2011), underscoring the importance of
neuron-glia communication for normal cerebellar function.
Astroglial Gain of Function: Astrocyte-Derived Toxicity
In ALS, it appears that astrocytes promote disease pathogenesis
not only because of their impaired glutamate uptake, but also
through a toxic gain of function. Such evidence for astrocyte-
mediated toxic effects upon motor neurons comes from both
in vitro and in vivo studies. When chimeric mice composed of
cells expressing either normal SOD1 protein or mutant SOD1protein were created, wild-type motor neurons encircled by
mutant nonneuronal cells suffered degeneration as denoted by
the formation of ubiquitin-positive protein aggregates (Clement
et al., 2003). Building on this finding, two later studies directly
modeled astrocyte-neuron interactions in coculture systems. In
one study, embryonic stem cells (ESCs) were derived from the
blastocysts of transgenic mice expressing either normal SOD1
or mutant SOD1, and these ESCs were differentiated into motor
neurons, and then plated onto monolayers of glia generated
from either nontransgenic mice, WT SOD1 transgenic mice, or
SOD1 G93A mutant transgenic mice (Di Giorgio et al., 2007).
Motor neurons obtained from either WT SOD1 transgenic
mice or mutant SOD1 transgenic mice exhibited signs of neuro-
degeneration and reduced survival only when cocultured with
glia from SOD1 transgenic mice that express the mutant SOD1
protein. Another study observed this same effect and showed
that culturing of primary motor neurons or ES-derived motor
neurons in media obtained from cultures of mutant SOD1 trans-
genic astrocytes was sufficient to induce apoptosis of motor
neurons (Nagai et al., 2007). Interestingly, conditioned media
from ALS1 SOD1 mouse microglia, cortical neurons, myocytes,
or fibroblasts was not toxic to motor neurons—only condi-
tioned media from ALS1 SOD1 mutant astrocytes possessed
this property. Although the specific molecule or protein
responsible for mutant SOD1 astrocyte toxicity eluded identifi-
cation in this study, SOD1 and glutamate were ruled out as
the offending substance (Nagai et al., 2007). Defining the
nature of this astrocyte-derived soluble toxin could yield
crucial insights into ALS disease pathogenesis and may have
therapeutic implications. The clinical relevance of astrocyte-
mediated neurotoxicity for FALS and SALS was recently demon-
strated by a provocative study in which neural progenitor cells
derived from the spinal cords of FALS and SALS patients
anddifferentiated into astrocyteswere sufficient to kill cocultured
motor neurons (Haidet-Phillips et al., 2011). Interestingly,
this study indicated that SOD1 appears to contribute to the
neurotoxicity imparted by SALS and FALS astrocytes, as knock-
down of SOD1in these astrocytes suppressed motor neuron
toxicity.
Neurodegenerative Diseases and the Innate Immune
Response
Innate immune responses include the initial cellular and molec-
ular reaction to the detection of pathogens or tissue injury. Key
components of the CNS innate immune response include the
complement cascade and cells capable of performing phagocy-
tosis, generating reactive oxygen species and signaling via cyto-
kines, chemokines, and additional immunomodulatory small
molecules to other cells involved in the response to injury or
pathogens. Evidence for the activation of the CNS innate
immune response in neurodegenerative diseases have been
extensively documented and recently reviewed (Prinz et al.,
2011). However, the mechanisms by which neuronal injury is
signaled to the immune system, and how this immune response
may subsequently influence the progression of the disease, have
only recently been elucidated. The principal mechanism through
which an innate immune response is initiated, involves signaling
through the TLR family of receptors (Crack and Bray, 2007;Neuron 73, March 8, 2012 ª2012 Elsevier Inc. 891
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Figure 3. Microglia Play Divergent Roles during Neurodegeneration
In the healthy CNS, microglia survey their immediate environment, and in this ‘‘resting state,’’ do not express inflammatory mediators. However, after exposure to
a number of chemical signals from damaged neurons, microglia respond rapidly and physically migrate to the site of injury. Respondingmicroglia may then adopt
a pattern of behavior similar to proinflammatory macrophages (shown in red), as they release molecules intended to protect against pathogens, including
neurotoxic cytokines, reactive oxygen species (ROS), and small molecules, such as quinolinic acid, that promote excitotoxicity. The release of cytokines and
chemokines can lead to the recruitment of additional inflammatory cells from adjacent blood vessels, and may also engage astrocytes in the proinflammatory
response. Alternatively, activated microglia may exhibit behaviors associated with anti-inflammatory macrophages (shown in green), secreting molecules that
promote tissue repair, and internalizing cellular debris including aggregated, misfolded proteins such as b-amyloid, through phagocytosis. Whether two distinct
populations of microglia exist that are committed to either of these response patterns, or all microglia can be induced to exhibit either response behavior when
exposed to the correct combination of signals, remains to be determined.
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role in binding a variety of pathogen associated molecular
pattern (PAMP) ligands common to pathogenic organisms (Akira
et al., 2001). More recently however, it has become clear that
injured cells, including neurons (Sloane et al., 2010), release
a class of molecules known as ‘‘danger associated molecular
pattern’’ (DAMP) ligands that also bind to TLR receptors and
initiate an innate immune response. The DAMP/TLR signaling
pathway, in addition to release of the chemokine CX3CL1 (previ-
ously known as fractalkine) by injured neurons (Streit et al.,
2005), explain how innate CNS immune response can produce
a strong inflammatory reaction, in the absence of pathogens,
that may impact disease onset and progression.
The CNS has a highly specialized innate immune system that
uniquely involves astrocytes and CNS resident leukocytes
known asmicroglia (Figure 3). Microglia typically express molec-892 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.ular tags associated with resting (noninflammatory) macro-
phages, but can adopt novel morphological and molecular
features associated with both pro- and anti-inflammatory states
in the context of neurodegenerative disease (Colton, 2009).
While inflammatory activation may typically be a secondary
response to primary neuronal injury, there is a great deal
of evidence suggesting that dysfunctional innate immune
responses actively contribute to neurodegeneration in HIV asso-
ciated neurodegeneration and autoimmune disorders of theCNS
(Kaul et al., 2005; Lassmann and van Horssen, 2011). In addition,
numerous examples of age-related alterations in the inflamma-
tory response are thought to contribute to the pathogenesis of
other disorders of aging, such as atheroscelerosis and diabetes.
Thus, it is possible that neurodegenerative diseases display age
dependency due to the loss of an optimized inflammatory
response in the CNS.
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In AD, there are many ways by which the innate immune system
influences disease pathogenesis. For example, inflammatory
phagocytic cells may modulate neurodegenerative pathology
in AD as they have been speculated to be involved in the clear-
ance of Ab from the CNS. It was consequently reasoned that
stimulating the inflammatory response to Ab via immunization
could increase Ab clearance, decrease plaque formation, and
ameliorate neurodegeneration (Hoozemans et al., 2001). Signifi-
cant resources have been, and continue to be spent on evalu-
ating a means to generate immunotherapy aimed at improving
Ab clearance from the CNS. Unfortunately, a clinical trial of Ab
immunization resulted in autoimmune encephalitis (Schenk,
2002), suggesting that modulating the immune response to Ab
may be a ‘‘double-edged sword.’’ Indeed, it is difficult to discern
whether the net effect of the innate immune response in AD is
neurotoxic or neuroprotective. However, when a mouse model
of AD was crossed onto a line deficit for the chemokine receptor
CCR2, thus preventing chemokine-induced infiltration of mono-
cytes across the blood-brain barrier, the animals developed
more rapid disease and increased Ab deposition (El Khoury
et al., 2007). Hence, monocyte infiltration into the CNS appears
critical to ameliorate AD progression, at least in mice. However,
subsequent studies suggest that resident microglia may have
a much more complex role in AD pathogenesis. Microglia and
neurons have a unique means for communication, with neurons
expressing the chemokine CX3CL1 and microglia expressing its
corresponding cognate receptor, CX3CR1. Injured neurons
release CX3CL1, which signals microglia migration to the site
of injury and initiation of an inflammatory response. When this
communication was blocked by genetic deletion of CX3CR1 in
a murine AD model, Ab plaque pathology was reduced (Lee
et al., 2010d). Taken together, these reports indicate that while
infiltrating monocytes are important for Ab clearance, the micro-
glial response to neurodegeneration may actually exacerbate
disease progression.
Huntington’s Disease
As in AD, the role of inflammation in HD pathogenesis may simi-
larly involve both peripheral and CNS-resident components
of the innate immune system. In patients with HD, increased
production of inflammatory cytokines can be detected many
years prior to symptomonset, and plasma levels of proinflamma-
tory cytokines correlate with symptom progression (Bjo¨rkqvist
et al., 2008). Circulating monocytes from HD patients are more
responsive to a proinflammatory signal than monocytes from
control patients, a finding that has been recapitulated in multiple
HD mouse models (Bjo¨rkqvist et al., 2008). This hyperreactivity
of monocytes may reflect functional alterations triggered by
the presence of mutant huntingtin protein. Whether such func-
tional alterations directly contribute to neurodegeneration in
HD remains to be determined. One mechanism whereby periph-
eral innate immune function could potentially influence neuron
survival or degeneration in HD involves the tryptophan catabo-
lism pathway, which has been shown to be altered by the
expression of mutant huntingtin in yeast (Giorgini et al., 2005).
One upstreammetabolite in this pathway, L-kynurenine is neuro-
protective, while downstreammetabolites, 3-hydroxykynurenine
and quinolinic acid, are neurotoxic (Za´dori et al., 2009). MSNsare preferentially susceptible to the toxicity of quinolinic acid
(Roberts et al., 1993). A recent study reported that pharmacolog-
ical inhibition of the rate-limiting enzyme in this pathway, kyneur-
enine 3-monooxygenase (KMO), markedly slowed disease
progression in HD mice (Zwilling et al., 2011). Since the KMO
inhibitor employed in this study does not cross the blood-
brain-barrier, the authors suggest that inhibition of KMO in the
peripheral innate immune system is sufficient to increase levels
of neuroprotective metabolites from the tryptophan catabolism
pathway in the CNS. Since KMO expression is promoted by
proinflammatory stimuli (Connor et al., 2008), the increased
inflammatory responses reported in HD peripheral monocytes
may enhance KMO expression and/or activity and exacerbate
neurodegeneration. Interestingly, KMO inhibition also amelio-
rated pathology in a murine ADmodel (Zwilling et al., 2011), sug-
gesting that a similar metabolic mechanism may comprise
another facet of CNS-innate immunity cross-talk involved in
AD neurodegeneration.
Parkinson’s Disease
Both pathological and positron emission tomography (PET)
studies have shown that patients with PD exhibit a robust inflam-
matory response in brain regions undergoing neurodegeneration
(Gerhard et al., 2006; McGeer et al., 1988; Ouchi et al., 2009;
Wersinger and Sidhu, 2002). Furthermore, as in AD, epidemio-
logical studies suggest that chronic users of nonsteroidal anti-
inflammatory drugs (NSAIDs) may have a decreased risk of PD
(Samii et al., 2009). TLR agonist molecules can be employed to
generate animal models of dopaminergic neuron degeneration
that recapitulate PD, and rare PD mutations that exacerbate
inflammatory responses also worsen the phenotype in certain
models of PD (Saijo et al., 2009). Furthermore, numerous animal
studies using toxin-induced models of PD have shown that
modulating the inflammatory response can ameliorate neuronal
loss (Wang et al., 2005). However, it remains unclear how these
models relate to the slowly progressive neurodegeneration that
occurs in patients with idiopathic or familial forms of PD. As
PD is associated with an abnormal accumulation of a-synuclein
into Lewy bodies, one hypothesis is that misfolded a-synuclein
induces an inflammatory response. This could occur either
through the release of a-synuclein into the extracellular space,
or by direct engulfment of a-synuclein as microglia participate
in the regulation of synaptic membranes (Zhang et al., 2005).
Interestingly, histological studies in PD patients graftedwith non-
diseased fetal dopaminergic neurons reveal that Lewy bodies
emerge in transplanted neurons (Kordower et al., 2008a; Li
et al., 2008). Specifically, only patients with a robust perigraft
inflammatory response were observed to have Lewy bodies in
grafted neurons, while grafted neurons survived without Lewy
pathology in patients lacking evidence of perigraft microglia
activation (Mendez et al., 2008). One parsimonious explanation
for these findings is that an immune response to the graft facili-
tates the spread of Lewy body pathology from the host to the
graft (Dawson, 2008). If this conjecture is valid, it raises the
intriguing possibility that disease-associated misfolded or
aggregate proteins such as a-synuclein can acquire prion-like
properties and that prion-like propagation of diseased proteins
from cell to cell may be facilitated by exposure to an inflamma-
tory milieu.Neuron 73, March 8, 2012 ª2012 Elsevier Inc. 893
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Rise of the Propagation Hypothesis
Of Prions and Prionoids
The prevailing view that neurodegenerative pathology is driven
by protein misfolding and generation of toxic conformers origi-
nated in the late 1990swith the observation that disease-causing
proteins such as a-synuclein and polyglutamine share common
amyloidogenic properties and cascades characteristic of
Alzheimer’s and prion diseases. A common theme of misfolded
protein toxicity thus links prion diseases with Alzheimer’s
disease, Parkinson’s disease, ALS, polyglutamine diseases,
and tauopathies. However, prion diseases have been viewed
as unique among the neurodegenerative proteinopathies, since
prions have the capacity for cell-to-cell and organism-to-
organism dissemination. The infectivity of prion protein is well
established, so much so that in its prion-like state, designated
as PrPSc, prion protein can induce nonpathogenic prion protein,
PrPc, to undergo a conformational change into the pathogenic
PrPsc state (Pan et al., 1993). In this conformational conversion,
which can even occur across species barriers in certain cases
(e.g., cow to human), pathogenic PrPsc seeds the transformation
of PrPc to PrPsc through a mechanisms that remains to be fully
elucidated. Within the last few years, studies of nonprion neuro-
degenerative proteinopathies have demonstrated in vitro cell-to-
cell transmission of protein aggregates (Desplats et al., 2009;
Frost et al., 2009; Magalha˜es et al., 2005; Mu¨nch et al., 2011;
Ren et al., 2009). Propagation of protein aggregates from one
cell to another has now been documented for several
neurodegenerative proteinopathies, and sometimes over large
distances—even traversing the blood-brain barrier (Clavaguera
et al., 2009; Desplats et al., 2009; Meyer-Luehmann et al.,
2006), raising the intriguing, but far fromproven notion that nonp-
rion neurodegenerative disorders are more prion-like (prionoid)
than we had imagined.
Alzheimer’s Disease
According to the amyloid cascade hypothesis, the pathogenesis
of AD begins with changes in Ab metabolism that promote the
production of the Ab42 peptide, which is followed by the forma-
tion of Ab aggregates from seeds of Ab42 peptides that grow
into fibrils and finally plaques (Hardy and Selkoe, 2002). The Ab
plaques then alter synaptic function and interfere with tau protein
metabolism to ultimately yield a neurodegenerative process in
cortical and hippocampal neurons. More than a decade ago,
evidence emerged that misfolded Ab42 peptide seeds from AD
patient brains can greatly accelerate amyloid plaque formation
in amyloid precursor protein (APP) transgenic mice (Kane
et al., 2000). The removal of Ab42 peptides from such brain
extracts or protein denaturation could prevent the promotion of
amyloid plaque formation in such mice (Meyer-Luehmann
et al., 2006); however, themechanistic basis of this phenomenon
remains unclear, though protein cofactors could be principally
involved. When follow-up studies with Ab42-containing brain
lysates, using oral, intravenous, intraocular, and intranasal
delivery schemes, failed to yield amyloidogenesis in the brains
of genetically susceptible mice (Eisele et al., 2009), the prion-
like properties of Ab42 peptide were questioned. Contrastingly,
more recent work has shown that intraperitoneal injection of
Ab42-containing brain lysate material dramatically promotes894 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.amyloid plaque formation in APP transgenic mice (Eisele et al.,
2010). Why was intraperitoneal delivery successful, while all
other delivery schemes failed? Although suggested explanations
must remain speculative, it is possible that earlier studies utilizing
diverse delivery schemes did not isolate propagation-competent
conformational forms of the Ab42 peptide. As the basis for the
success of the intraperitoneal study is also unclear, future exper-
imentation should investigate if the Ab42 peptide seeds are taken
up by macrophages and monocytes that then travel to the brain
parenchyma via the cerebral vasculature, as has been proposed
(Eisele et al., 2010), or if the Ab42 peptide seeds exist extracellu-
larly without entering membrane-bound structures or cells
on their journey to the CNS. In vivo studies in which the Ab42
peptide seeds are tagged or tracked using an amyloid-binding
compound, such as Pittsburgh compound B (PIB) (Klunk et al.,
2004), might yield insight into the nature of the propagation
process.
Parkinson’s Disease
As mentioned previously, cell transplantation studies in PD
patients have implicated the possible prionoid propensity of
a-synuclein, as autopsies revealed that Lewy body pathology
was present not only in the patients’ own neurons, but also in
the donor neurons (Kordower et al., 2008a, 2008b; Li et al.,
2008, 2010). In a number of studies further assessing cell-cell
transmission of a-synuclein, uptake of a-synuclein from the
medium into cells grown in culture was documented and
observed to result in Lewy body-like aggregates in recipient cells
(Danzer et al., 2007, 2009; Luk et al., 2009; Nonaka et al., 2010;
Waxman and Giasson, 2010). These aggregates consisted of
both the exogenous recombinant a-synuclein protein supplied
in the media, and endogenous cellular a-synuclein protein. In
addition to this in vitro work, one group has investigated propa-
gation of a-synuclein proteotoxicity in vivo, and found that
mouse cortical neuron stem cells engrafted into the hippo-
campus of Thy-1 a-synuclein transgenic mice exhibited uptake
of transgenic human a-synuclein protein as soon as one week
after transplant (Desplats et al., 2009). By four weeks after
engraftment, 15% of the transplanted neurons displayed a-syn-
uclein immunoreactivity, which resembled inclusion bodies in
a subset of neurons revealing this propagation. Other studies
have also found evidence for transfer of a-synuclein from neuron
to astroglia or vice versa. In a-synuclein transgenic mice with
a platelet-derived growth factor (PDGF) promoter, expression
of a-synuclein is restricted to neurons, yet prominent accumula-
tion of a-synuclein is present in glial cells, and transmission of
a-synuclein from neurons to astroglia was confirmed in coculture
experiments (Lee et al., 2010a). In a multiple system atrophy
model, transgenic mice exclusively expressing a-synuclein in
oligodendrocytes develop a-synuclein-containing axonal inclu-
sions as well as the classic glial cytoplasmic inclusions (Yazawa
et al., 2005). Hence, numerous studies strongly support the
conclusion that a-synuclein can move from cell-to-cell and this
process can involve different glial cell types as well as neurons.
Tauopathy
Aggregation of the microtubule-associated protein tau is
a neuropathological feature of roughly two dozen neurodegener-
ative disorders in humans. The process of tau protein aggrega-
tion is linked to posttranslational modification, in particular
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that is most prone to aggregate and produce neurotoxicity
(Haass, 2010). In AD, hyperphosphorylated tau isoforms are
initially apparent in the enterorhinal cortex and then become
detectable in the hippocampus and neocortex (Braak and Braak,
1991), suggesting that the histopathology is focal and then prop-
agates to adjacent regions of the brain. Similar to Ab- and a-syn-
uclein peptides, exogenous extracellular mutant tau protein can
be taken up by cells, and once internalized, will promotemisfold-
ing of endogenously expressed tau protein (Frost et al., 2009).
The relevance of tau propagation is further supported in vivo
by a provocative series of experiments performed in tau trans-
genic mice (Clavaguera et al., 2009). In this work, mice express-
ing WT tau develop prominent filamentous tau inclusions after
receiving hippocampal and cortical injection of brain homoge-
nates from transgenic mice harboring the pathological phos-
pho-tau mutation (P301S) (Clavaguera et al., 2009). Indeed,
this acquired filamentous tau pathology did not remain confined
to the injected regions, but actually spread beyond the injection
zone to neighboring brain regions (Clavaguera et al., 2009). Two
very recent studies further support a role for cell-to-cell transmis-
sion of misfolded tau protein, as transgenic expression of mutant
P301L tau restricted to the enterorhinal cortex spreads to synap-
tically connected neurons in the hippocampus, recapitulating the
progressive neurofibrillary tangle histopathology characteristic
of AD (de Calignon et al., 2012; Liu et al., 2012). These findings
suggest that propagation of tau protein aggregation, which
occurs intracellularly, could be operating in a variety of disorders
featuring tau pathology.
Amyotophic Lateral Sclerosis
ALS is a highly heterogeneous disorder in terms of clinical
presentation and neuropathology. Thus, there has been interest
in deconstructing the natural history of ALS (Ravits and La
Spada, 2009), which has revealed a number of themes, including
focality of clinical onset, followed by contiguous spread of motor
disease. Focality of clinical onset refers to the fact that most ALS
patients initially present with motor deficits that are confined to
a particular region of the neuraxis. Thereafter, motor deficits
follow a relatively predictable pattern, as the next regions to
become involved are typically adjacent ipsilaterally distributed
motor units. ALS natural history is thus compatible with a propa-
gating process that is orderly and moves locally, as opposed to
distally. Recent work on familial ALS, due to mutations in SOD1,
now suggests that cell-to-cell transmission of mutant SOD1
aggregates can occur (Chia et al., 2010; Mu¨nch et al., 2011).
Much like in the AD and PD studies discussed above, in vitro
aggregation of both wild-type and mutant SOD1 protein is
observed upon exogenous addition of isolated spinal tissue
frommice expressingmutant SOD1 (Chia et al., 2010). In another
recent study, supplementation of the cell culture media with
mutant SOD1 protein aggregates was sufficient for uptake of
the SOD1 aggregates by Neuro2a cells, and internalization of
mutant SOD1 protein aggregates drove aggregation of endoge-
nously expressed soluble mutant SOD1 protein (Mu¨nch et al.,
2011). Cell-to-cell spreading of mutant SOD1 protein aggregates
then continued, despite the lack of contact between cells,
through a process that was ATP-dependent, required actin fila-
ment formation, and involved lipid raft-mediated macropino-cytosis. While these findings are provocative, further work is
required to determine if this propagation of aggregates occurs
in vivo or is relevant to TDP-43 protein aggregation, a proteotox-
icity emerging as a cardinal feature of sporadic ALS (Mackenzie
et al., 2010).
Polyglutamine-Expansion Diseases
While adoption of an alternative structure represents a key step
in the pathogenic cascade for polyglutamine disease proteins,
considerable work suggests that amyloid-like protein aggre-
gates in these disorders are not the toxic species, but rather
coincident with the production of toxic conformers whose exact
nature remains uncertain (Arrasate et al., 2004; Chia et al., 2010;
Poirier et al., 2002;Wacker et al., 2004). Nonetheless, production
of protein aggregates always indicates that a process of poly-
glutamine proteotoxicity is underway; hence, if dynamic inter-
conversion between toxic conformers and aggregates is
ongoing, then cell-to-cell transmission of altered polyglutamine
species could promote propagation of pathology. In an in vitro
investigation, a highly amyloidogenic polyglutamine species
was added to the culture media of HEK293 cells stably express-
ing a nonpathogenic huntingtin protein fragment (Ren et al.,
2009). Cellular uptake of the toxic polyglutamine species unex-
pectedly led to aggregation of the nonpathogenic huntingtin
protein, which normally does not form aggregates. Furthermore,
the aggregation of huntingtin-Q25 persisted through multiple
rounds of cell division, but such aggregation could not be
induced with unrelated amyloidogenic proteins, such as yeast
Sup35 or Ab. In an independent study, huntingtin protein aggre-
gation was monitored with a fluorescent signal, and cell-to-cell
transmission of huntingtin protein oligomers was documented
(Herrera et al., 2011). Further studies will be required to validate
the significance and relevance of such cell-to-cell spreading in
disease pathogenesis.
Mechanisms of Cell-to-Cell Propagation
If it is true that misfolded proteins can spread from one cell to
another, then the obvious question that we must address is
how this occurs. One approach to this issue is to recognize
that the process can operate in at least two different ways: (1)
by extracellular release and uptake or (2) by delivery within
membrane-bound structures (Figure 4). In this section, we will
briefly review potential pathways by which misfolded proteins
could achieve intercellular transit.
Misfolded proteins that are aggregate-prone pose a continual
challenge to degradative pathways, forcing neurons to heavily
rely on autophagy for proteostasis. Hence, misfolded protein
conformers are typically directed to membrane-bound struc-
tures, in particular autophagosomes that ultimately fuse with
endosomes or lysosomes. Under conditions of suboptimal lyso-
some function, these membrane-bound structures will become
exocytotic vesicles and release their contents into the extracel-
lular space, as has been shown for a-synuclein (Jang et al.,
2010). Although release of vesicle-bound materials into the
extracellular space has been viewed as the consequence of
impaired function, autophagosomes may normally become
exocytotic vesicles and intentionally expel their contents into
the extracellular space. The existence of two alternative desti-
nies for autophagosomes may be restricted to a specialized
version of the autophagy pathway, named ‘‘quality-controlNeuron 73, March 8, 2012 ª2012 Elsevier Inc. 895
Figure 4. Proposed Mechanisms to Account for Cell-to-Cell Transmission of Misfolded Proteins
(A) Exocytosis/endocytosis. Misfolded proteins can be packaged into exocytotic vesicles (top left; arrows), which fuse with the cell membrane and release their
contents into the extracellular space.Misfolded proteinsmay be delivered to preautophagic vesicles thatmature into double-membrane bound autophagosomes
(top right; arrows). One possible fate of certain autophagosomes is to fuse with the cell membrane and release their contents into the extracellular space. Once in
the extracellular space, misfolded proteins can be taken up by cells via lipid raft-mediated endocytosis (bottom left; zigzags represent lipid rafts), or more likely by
receptor-mediated endocytosis (bottom right; half rectangle with oval indentation represents receptor).
(B) Propagation without membrane-bound transport. Misfolded proteins may move from one cell to another via intercellular bridges, known as ‘‘tunneling
nanotubes’’ (left; arrows). Another route for cell-to-cell transfer of misfolded proteins is within exosomes, small membrane-bound vesicles (green circles) that can
form within multivesicular bodies (orange circle), which are released and endocytosed by a neighboring cell (right; arrows). Such exosomes can bud off of their
original cell and travel large distances before fusing with the membrane of another cell. How misfolded protein conformers, sequestered in endosomes, gain
access to the cytosolic compartment remains unclear.
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post-mitotic cells, and is tasked with maintaining protein and
mitochondrial quality control. The ability of quality control auto-
phagy to promote degradation of sequestered contents has
been demonstrated for parkin-regulated mitophagy (Lee et al.,
2010c). This pathway, which requires HDAC6 to promote fusion
of autophagosomes with lysosomes (Lee et al., 2010b), may
allow autophagosomes to achieve exocytotic secretion of
protein aggregates, when the capacity for lysosomal degrada-
tion is exceeded—though this is yet to demonstrated. Thus,
neurons may direct amyloidogenic proteins to the autophagy
pathway not only to promote their intracellular degradation but
also to enable the cell to eliminate themby a process of secretion
via exocytosis.
Once in the extracellular space, how do toxic protein
conformers gain access to cells? Although lipophilic proteins
such as monomeric a-synuclein could in theory passively diffuse
across cellular membranes (Steiner et al., 2011), this method of
entry is likely the exception. Another path of entry could be via
lipid raft-mediated endocytosis, which has been proposed for
both Ab- and a-synuclein (Park et al., 2009; Saavedra et al.,
2007). However, a-synuclein has unique biophysical properties896 Neuron 73, March 8, 2012 ª2012 Elsevier Inc.and even can associate with key proteins that regulate endocy-
tosis (Desplats et al., 2009). Hence, most toxic peptides likely
enter cells via receptor-mediated endocytosis. The rationale
for the existence of such a pathway may be for cells to actively
remove misfolded proteins from the extracellular space and
achieve their destruction. According to this model, the burden
of eliminating such toxic proteins would be shared between
different cells and cell types.
Another mode for cell-to-cell transmission of misfolded
proteins is within membrane-bound structures. One highly likely
candidate for this process is the exosome, a small membrane-
bound vesicle formed within almost all cell types in an intracel-
lular membrane-bound structure known as a multivesicular
body (Chaput and The´ry, 2011). Exosomes bud off, and then
either fuse with lysosomes or fuse with the plasma membrane,
where they are released as membrane-bound structures that
can travel to nearby cells, or voyage to distant tissues via the
circulation. Evidence for the role of exosomes in propagation
has come from studies that have documented the packaging
of a-synuclein protein into exosomes, prior to intercellular trans-
fer (Alvarez-Erviti et al., 2011; Emmanouilidou et al., 2010).
Similar investigations have also implicated exosomes in the
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et al., 2011; Vella et al., 2007).
Yet another process of intercellular membrane-bound
communication involves structures known as tunneling nano-
tubes, which are transient, long, actin-rich projections that
directly connect cells to one another. At this time, the only
evidence for tunneling nanotubes as a means of intercellular
transmission of misfolded proteins comes from studies of prion
disease. This work, performed exclusively in cell culture, re-
vealed that PrPsc proteins can move from an infected neuron
to an uninfected neuron, or from bone-marrow derived dendritic
cells to an uninfected primary neuron (Gousset et al., 2009). The
discovery of tunneling nanotubes underscores the diversity of
pathways by which cell-to-cell communication is achieved in
the nervous system, and suggests that other processes likely
remain to be elucidated.
Unsolved Questions and Directions for the Future
The work reviewed here illustrates how intercellular communica-
tion may go awry within the CNS. Additional examples of altered
cell-cell communication will likely be described over the coming
years, strengthening the evidence for a multi-hit model for
neurodegenerative disease. Three critical questions regarding
this hypothesis, however, remain to be addressed: (1) what is
the pathophysiological relationship between monogenic and
sporadic forms of neurodegenerative disease? (2) Howdoes bio-
logical aging influence disease onset and progression? And (3)
how do diseases produced by ubiquitously expressed disease
proteins cause selective patterns of neurodegeneration? The
multi-hit hypothesis enables understanding of the first question
by providing a context to consider how changes in response to
a specific heritable mutation might be recapitulated by sporadic
events. For example, somatic mutations, epigenetic modifica-
tion, acquired mitochondrial dysfunction, or misfolded protein
accumulation—in response to environmental exposures (e.g.,
toxins, stress etc) or normal aging, might sum to produce the
same net effect as inheriting an extra copy of a-synuclein. Addi-
tionally, if CNS homeostasis requires that we maintain certain
patterns of cell-cell communication, then the integration of aber-
rant subclinical events could yield a degenerative disease due
to progressive loss of function in such cellular communication.
For example, if communication between two neuronal popula-
tions, ‘‘A’’ and ‘‘B,’’ is required for their normal survival and func-
tion, while population B supports populations ‘‘C’’ and ‘‘D,’’ then
loss of function in A type neurons could determine the survival of
all four cell types (and then additional cells that depend upon
the three affected groups). Such cellular network relationships
may have several levels of complexity. One type of cell-cell
communication could be involved in initiating a protein misfold-
ing event, while interactions with a second cell type could influ-
ence the ability to remove or degrade a misfolded protein. We
hypothesize that the mechanism for selective vulnerability
involves specific alterations in cell-cell communication, and
thus may consist of a unique series of events for each disease.
For example, MSNs, the most vulnerable neuron population in
HD, may have cell-autonomous vulnerabilities shared with other
neuronal populations that degenerate later in the course of
disease. But the MSNs may also depend upon signals fromspecific afferent or target neurons, making them exquisitely
vulnerable to an altered balance between a certain molecule
(e.g., kynurenine) and its neurotoxicmetabolites. Thus, themuta-
tion responsible for HD could alter the function of multiple cell
types, and it would be the dysfunction of these other cell types
that together make MSNs selectively vulnerable.
When one considers the complexity of the CNS, it should
come as little surprise that the basis of nervous system disease
would be similarly complicated. Neurons do not exist in isolation;
hence, neurodegenerative diseases must be viewed as resulting
from processes that ultimately target neurons—but are by no
means restricted to them. In this review, we have attempted to
delineate advances in our understanding of neurodegenerative
disease pathogenesis, by focusing upon pathological processes
occurring between different cells, some between identical cell
types, but many involving cells of distinct lineage. These insights
and discoveries, many quite recent, underscore the increasingly
pivotal role for disrupted or altered cell-cell interactions in neuro-
logical disorders. While a ‘‘systems cell biology’’ approach to
neurodegenerative disease may seem daunting, we have made
great strides in developing methods and models that now
permit us to evaluate a pathological process in finer detail and
in a more physiological context than ever before. For example,
approaches that enable both time and cell type specific gene
expression in animal models will make it possible to determine
if and when disease gene expression in specific cell populations
contribute to the disease phenotype. In addition, novel imaging
methods enable the study of specific cell populations in vivo
over longer periods of time and will reveal how interacting pop-
ulations influence each other’s survival. Another important line
of research for the future will involve isolating specific cellular
populations from CNS tissue in order to characterize the distinct
genomic, proteomic and even epigenetic alterations that occur
during disease onset or progression. Incorporating such strate-
gies into our dissection of the mechanistic basis of neurodegen-
erative disease must be a goal for future studies, as it bodes well
for greater success in deconstructing the cellular and the molec-
ular pathophysiology of these devastating disorders. If we can
achieve this goal, we increase the likelihood of developing effec-
tive therapies for numerous currently untreatable neurological
disorders.
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